A de novo nonsense variant in the DMD gene associated with X-linked dystrophin-deficient muscular dystrophy in a cat.Nozomu Yokoyama; Yuki Matsumoto; Takahisa Yamaguchi; Kazuki Okada; Ryohei Kinoshita; Genya Shimbo; Hisashi Ukawa; Ryuga Ishii; Kensuke Nakamura; Jumpei Yamazaki; Mitsuyoshi Takiguchi
Journal of veterinary internal medicine, 2024年04月13日,
［国際誌］英語, 研究論文（学術雑誌）, BACKGROUND: X-linked dystrophin-deficient muscular dystrophy (MD) is a form of MD caused by variants in the DMD gene. It is a fatal disease characterized by progressive weakness and degeneration of skeletal muscles. HYPOTHESIS/OBJECTIVES: Identify deleterious genetic variants in DMD by whole-genome sequencing (WGS) using a next-generation sequencer. ANIMALS: One MD-affected cat, its parents, and 354 cats from a breeding colony. METHODS: We compared the WGS data of the affected cat with data available in the National Center for Biotechnology Information database and searched for candidate high-impact variants by in silico analyses. Next, we confirmed the candidate variants by Sanger sequencing using samples from the parents and cats from the breeding colony. We used 2 genome assemblies, the standard felCat9 (from an Abyssinian cat) and the novel AnAms1.0 (from an American Shorthair cat), to evaluate genome assembly differences. RESULTS: We found 2 novel high-impact variants: a 1-bp deletion in felCat9 and an identical nonsense variant in felCat9 and AnAms1.0. Whole genome and Sanger sequencing validation showed that the deletion in felCat9 was a false positive because of misassembly. Among the 357 cats, the nonsense variant was only found in the affected cat, which indicated it was a de novo variant. CONCLUSION AND CLINICAL IMPORTANCE: We identified a de novo variant in the affected cat and next-generation sequencing-based genotyping of the whole DMD gene was determined to be necessary for affected cats because the parents of the affected cat did not have the risk variant.
Diverse genome-wide DNA methylation alterations in canine hepatocellular tumours.Yu Asari; Jumpei Yamazaki; Oo Thandar; Tamami Suzuki; Keisuke Aoshima; Kyosuke Takeuchi; Ryohei Kinoshita; Sangho Kim; Kenji Hosoya; Teita Ishizaki; Yumiko Kagawa; Jaroslav Jelinek; Shoko Yokoyama; Noboru Sasaki; Hiroshi Ohta; Kensuke Nakamura; Mitsuyoshi Takiguchi
Veterinary medicine and science, 2023年07月22日,
［国際誌］英語, 研究論文（学術雑誌）, BACKGROUND: Canine hepatocellular tumours (HCTs) are common primary liver tumours. However, the exact mechanisms of tumourigenesis remain unclear. Although some genetic mutations have been reported, DNA methylation alterations in canine HCT have not been well studied. OBJECTIVES: In this study, we aimed to analyse the DNA methylation status of canine HCT. METHODS: Tissues from 33 hepatocellular carcinomas, 3 hepatocellular adenomas, 1 nodular hyperplasia, 21 non-tumour livers from the patients and normal livers from 5 healthy dogs were used. We analysed the DNA methylation levels of 72,367 cytosine-guanine dinucleotides (CpG sites) in all 63 samples. RESULTS AND CONCLUSIONS: Although a large fraction of CpG sites that were highly methylated in the normal liver became hypomethylated in tumours from most patients, we also found some patients with less remarkable change or no change in DNA methylation. Hierarchical clustering analysis revealed that 32 of 37 tumour samples differed from normal livers, although the remaining 5 tumour livers fell into the same cluster as normal livers. In addition, the number of hypermethylated genes in tumour livers varied among tumour cases, suggesting various DNA methylation patterns in different tumour groups. However, patient and clinical parameters, such as age, were not associated with DNA methylation status. In conclusion, we found that HCTs undergo aberrant and diverse patterns of genome-wide DNA methylation compared with normal liver tissue, suggesting a complex epigenetic mechanism in canine HCT.
Successful treatment of sclerosing encapsulating peritonitis in a cat using bioresorbable hyaluronate-carboxymethylcellulose membrane after surgical adhesiolysis and long-term prednisoloneNozomu Yokoyama; Ryohei Kinoshita; Hiroshi Ohta; Kazuki Okada; Genya Shimbo; Kazuyoshi Sasaoka; Noriyuki Nagata; Noboru Sasaki; Keitaro Morishita; Kensuke Nakamura; Yumiko Kagawa; Mitsuyoshi Takiguchi
Journal of Feline Medicine and Surgery Open Reports, 9, 2, SAGE Publications, 2023年07月
研究論文（学術雑誌）, Case summary
An 8-year-old neutered male domestic shorthair indoor cat was presented with an 8-week history of intermittent vomiting, anorexia and weight loss that had been unresponsive to supportive treatment. Abdominal ultrasound revealed plication of the small intestine and fluid accumulation proximal to the lesion, and a linear foreign body was suspected. An exploratory celiotomy showed cocoon-like encapsulation of the entire intestine. Surgical adhesiolysis and full-thickness biopsy were performed, and histopathologic examination revealed mild thickening of the visceral peritoneum with fibrin deposition, as well as mild neutrophil and lymphocyte infiltration. These findings were compatible with sclerosing encapsulating peritonitis (SEP). The cat recovered well postoperatively and was discharged the next day. Prednisolone was administered for 7 weeks to prevent recurrence of SEP. Five months after surgery, the cat was re-presented with anorexia and chronic vomiting. Based on the clinical examination findings, recurrent SEP was suspected. At the second surgery, surgical adhesiolysis was repeated and a bioresorbable hyaluronate-carboxymethylcellulose membrane was used to cover the serosal surface and thus prevent adhesion formation. Histopathologic findings of the peritoneal biopsy specimen confirmed SEP. Long-term prednisolone treatment (1 mg/kg for the first dose and 0.5 mg/kg every 48 h for maintenance) was administered postoperatively. The cat survived for more than 1239 days without recurrence.
Relevance and novel information
To our knowledge, this is the first report of SEP in a cat with long-term survival. The use of a bioresorbable hyaluronate-carboxymethylcellulose membrane and long-term prednisolone treatment may have prevented short-term and long-term recurrence, respectively, in this case.
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant MelanomaTatsuya Deguchi; Naoya Maekawa; Satoru Konnai; Ryo Owaki; Kenji Hosoya; Keitaro Morishita; Motoji Nakamura; Tomohiro Okagawa; Hiroto Takeuchi; Sangho Kim; Ryohei Kinoshita; Yurika Tachibana; Madoka Yokokawa; Satoshi Takagi; Yukinari Kato; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Cancers, 15, 11, 3013, 3013, MDPI AG, 2023年06月01日,
［査読有り］研究論文（学術雑誌）, Although immune checkpoint inhibitors (ICIs), such as the anti-programmed death-ligand 1 (PD-L1) antibody, have been developed for the treatment of canine malignant melanoma, desirable clinical efficacies have not been achieved. Recent studies in humans have suggested that radiation therapy (RT) combined with ICIs induces robust systemic antitumour immunity in patients with cancer. This study retrospectively examined the therapeutic efficacy of combination therapy (hypofractionated RT and anti-PD-L1 antibody [c4G12]) in dogs with pulmonary metastatic oral malignant melanoma. The intrathoracic clinical benefit rate (CBR)/median overall survival (OS) in the no RT (n = 20, free from the effect of RT), previous RT (n = 9, received RT ≤8 weeks prior to the first c4G12 dose), and concurrent RT (n = 10, c4G12 therapy within ±1 week of the first RT fraction) groups were 10%/185 days, 55.6%/283.5 days (p < 0.05 vs. no RT group), and 20%/129 days (p > 0.05 vs. no RT group), respectively. The adverse events were considered to be tolerable in the combination therapy. Thus, hypofractionated RT before the initiation of c4G12 therapy can be an effective approach for enhancing the therapeutic efficacy of immunotherapy, with acceptable safety profiles. Further prospective clinical studies are required to confirm the findings of this study.
Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.Naoya Maekawa; Satoru Konnai; Kenji Hosoya; Sangho Kim; Ryohei Kinoshita; Tatsuya Deguchi; Ryo Owaki; Yurika Tachibana; Madoka Yokokawa; Hiroto Takeuchi; Yumiko Kagawa; Satoshi Takagi; Hiroshi Ohta; Yukinari Kato; Satoshi Yamamoto; Keiichi Yamamoto; Yasuhiko Suzuki; Tomohiro Okagawa; Shiro Murata; Kazuhiko Ohashi
PloS one, 18, 10, e0291727, 2023年,
［国際誌］英語, 研究論文（学術雑誌）, Immune checkpoint inhibitors (ICIs) have been developed for canine tumour treatment, and pilot clinical studies have demonstrated their antitumour efficacy in dogs with oral malignant melanoma (OMM). Although ICIs have been approved for various human malignancies, their clinical benefits in other tumour types remain to be elucidated in dogs. Here, we conducted a clinical study of c4G12, a canine chimeric anti-PD-L1 antibody, to assess its safety and efficacy in dogs with various advanced malignant tumours (n = 12) at the Veterinary Teaching Hospital of Hokkaido University from 2018 to 2023. Dogs with digit or foot pad malignant melanoma (n = 4), osteosarcoma (n = 2), hemangiosarcoma (n = 1), transitional cell carcinoma (n = 1), nasal adenocarcinoma (n = 1), B-cell lymphoma (n = 1), or undifferentiated sarcoma (n = 2) were treated with 2 or 5 mg/kg c4G12 every 2 weeks. Treatment-related adverse events of any grade were observed in eight dogs (66.7%), including elevated aspartate aminotransferase (grade 3) in one dog (8.3%) and thrombocytopenia (grade 4) in another dog (8.3%). Among dogs with target disease at baseline (n = 8), as defined by the response evaluation criteria for solid tumours in dogs (cRECIST), one dog with nasal adenocarcinoma and another with osteosarcoma experienced a partial response (PR), with an objective response rate of 25.0% (2 PR out of 8 dogs; 95% confidence interval: 3.2-65.1%). These results suggest that c4G12 is safe and tolerable and shows antitumor effects in dogs with malignant tumours other than OMM. Further clinical studies are warranted to identify the tumour types that are most likely to benefit from c4G12 treatment.
犬尿路上皮癌におけるPDXモデルの樹立
森下 大暉; 木之下 怜平; 青島 圭佑; 細谷 謙次; 山崎 淳平; 滝口 満喜
日本獣医学会学術集会講演要旨集, 165回, [B2P, 03], (公社)日本獣医学会, 2022年09月
日本語
イヌ悪性黒色腫細胞株における放射線照射で生じる上皮間葉転換とDNAメチル化の関与
田邊 裕晶; 安井 博宣; 山崎 淳平; 木之下 怜平; 山下 晃矢; 加藤 千博; 稲波 修
日本獣医学会学術集会講演要旨集, 165回, [I1A, 14], (公社)日本獣医学会, 2022年09月
日本語
Systemic mucoid degeneration of the arterial tunica intima in a young dogYoshiki Ichikawa; Mizuki Heishima; Kristin Vyhnal; Keisuke Aoshima; Kazuyoshi Sasaoka; Ryohei Kinoshita; Atsushi Kobayashi; Mitsuyoshi Takiguchi; Takashi Kimura
Journal of Veterinary Diagnostic Investigation, 34, 1, 94, 97, SAGE Publications, 2021年09月04日,
［査読有り］研究論文（学術雑誌）, A 27-mo-old, spayed female mixed-breed dog was presented with left forelimb pain, which progressed to full thickness necrosis of the soft tissues of multiple limbs. Clinical imaging and postmortem examination suggested multiple large arterial thromboemboli. Histologic examination of vascular lesions revealed markedly thickened tunica intima with polypoid intraluminal projections, which partially to entirely occluded the arterial lumen. The expanded tunica intima was comprised of intimal accumulation of Alcian blue–positive matrix with scattered spindle-to-satellite cells. These cells were positive for von Willebrand factor and vimentin but negative for α–smooth muscle actin, suggesting endothelial origin. Deposition of the intimal mucoid matrix was observed in the elastic and muscular arteries associated with regional ischemic changes. Mucoid emboli, likely from fragmentation of proliferative intimal tissue, were identified in smaller vessels supplied by affected arteries. Based on these findings, we diagnosed systemic mucoid degeneration of the arterial tunica intima. Such systemic arterial degeneration characterized by deposition of mucoid matrix in the tunica intima has not been reported previously in dogs, to our knowledge, and should be distinguished from thromboembolism and other degenerative vascular diseases.
イヌの肝細胞腫瘍におけるDNAメチル化の網羅的解析
淺利 友; 山崎 淳平; Oo Thander; 細谷 謙次; 金 尚昊; 木之下 怜平; 竹内 恭介; 賀川 由美子; 佐々木 東; 中村 健介; 滝口 満喜
日本獣医学会学術集会講演要旨集, 164回, [HSO, 30], (公社)日本獣医学会, 2021年09月
日本語
Detection of human epidermal growth factor receptor 2 overexpression in canine anal sac gland carcinoma.Sho Yoshimoto; Daiki Kato; Satoshi Kamoto; Kie Yamamoto; Masaya Tsuboi; Masahiro Shinada; Namiko Ikeda; Yuiko Tanaka; Ryohei Yoshitake; Shotaro Eto; Kohei Saeki; James Kenn Chambers; Ryohei Kinoshita; Kazuyuki Uchida; Ryohei Nishimura; Takayuki Nakagawa
The Journal of veterinary medical science, 81, 7, 1034, 1039, 2019年07月19日,
［査読有り］,
［国内誌］英語, 研究論文（学術雑誌）, Canine anal sac gland carcinoma (ASGC) frequently occurs in the apocrine glands of the canine anal sac and shows aggressive biological behavior. The expression of human epidermal growth factor receptor 2 (HER2) has been reported in various human and canine tumors. HER2 is a promising therapeutic target of these tumors, and HER2-targeted drugs, such as trastuzumab and lapatinib, have improved the outcome of these patients. In this study, HER2 expression in ASGC was evaluated to investigate its potential as a therapeutic target for canine ASGC. HER2 mRNA expression in surgically resected ASGC tissues was significantly higher than that in normal anal sac tissue. To evaluate the expression of HER2 protein, paraffin-embedded ASGC tissues were immunohistochemically evaluated. Strong and broad staining of HER2 was detected in ASGC tissues, while HER2 was weakly to moderately stained in normal anal sac apocrine glands and squamous epithelia. The degree of HER2 expression in ASGC tissues was scored based on its intensity and positivity (score: 0-3+). Scoring of HER2 expression revealed 6 samples (24%) scored 3+, 14 (56%) scored 2+, and 5 (20%) scored 1+, with no samples scoring 0. In all, 80% of canine ASGC tissues were positive for HER2 (scored ≥2+). Furthermore, putative HER2-overexpressed cells in ASGC were detected with trastuzumab by flow cytometry. These preliminary data may lead to further evaluation of the role of HER2 in canine ASGC as a mechanism of malignancy and as a therapeutic target for HER2-targeted therapy.
Immunohistochemical evaluation of HER2 expression in canine thyroid carcinoma.Sho Yoshimoto; Daiki Kato; Satoshi Kamoto; Kie Yamamoto; Masaya Tsuboi; Masahiro Shinada; Namiko Ikeda; Yuiko Tanaka; Ryohei Yoshitake; Shotaro Eto; Kohei Saeki; James Chambers; Ryohei Kinoshita; Kazuyuki Uchida; Ryohei Nishimura; Takayuki Nakagawa
Heliyon, 5, 7, e02004, 2019年07月,
［査読有り］,
［国際誌］英語, 研究論文（学術雑誌）, The human epidermal growth factor receptor 2 (HER2) is expressed in various human cancers including thyroid cancers (TC) and is used as a diagnostic marker and therapeutic target. Canine TC (cTC), the most common endocrine malignancy in dogs, shows a high metastasis rate, and HER2-targeted therapy could be a candidate for treatment. Here, we immunohistochemically evaluated HER2 expression in 21 paraffin-embedded cTC tissues and scored the degree of expression based on intensity and positivity (score: 0-3+). Four samples (19%) scored 3+; 6 (29%), 2+; 7 (33%), 1+; and 4 (19%), 0. Therefore, 48% of the cTC tissues were HER2 positive (scored ≥2+). These data may lead to further evaluation of the role of HER2 in cTC as a mechanism of malignancy and a therapeutic target.
心筋症に伴う血栓塞栓症による消化管壊死が疑われた猫1例
石川 恭平; 中川 泰輔; 水野 壮司; 山本 貴恵; 木之下 怜平; 長久保 大; 坪井 誠也; チェンバーズ・ジェームズ; 内田 和幸; 大野 耕一; 辻本 元
日本獣医麻酔外科学雑誌, 50, Suppl.1, 325, 325, (一社)日本獣医麻酔外科学会, 2019年06月
日本語
Evaluation of immunohistochemical staining with PMab-38, an anti-dog podoplanin monoclonal antibody, in various canine tumor tissues.
Kiname K; Yoshimoto S; Kato D; Tsuboi M; Tanaka Y; Yoshitake R; Eto S; Shinada M; Chambers J; Saeki K; Kinoshita R; Yamada S; Uchida K; K. Kaneko M; Nishimura R; Kato Y; Nakagawa T
Japanese Journal of Veterinary Research, 67, 1, 25, 34, 2019年02月, ［査読有り］
英語, 研究論文（学術雑誌）
Histopathologic and Immunohistochemistry Findings in Feline Renal Cell Carcinoma.Isao Matsumoto; James K Chambers; Kazumi Nibe; Ryohei Kinoshita; Ryohei Nishimura; Hiroyuki Nakayama; Kazuyuki Uchida
Veterinary pathology, 55, 5, 663, 672, SAGE Publications, 2018年09月,
［査読有り］,
［国際誌］英語, 研究論文（学術雑誌）, The biological behavior and immunohistochemical features of feline renal cell carcinoma (RCC) have not been well characterized. In the present study, immunohistochemical examinations were performed in 12 feline cases of RCC. The RCC consisted of solid ( n = 2), solid-tubular ( n = 2), tubular ( n = 3), papillary ( n = 2), tubulopapillary ( n = 2), and sarcomatoid ( n = 1) type lesions. Of the cases with RCC, 1 developed metastatic disease and 6 cases had no evidence of recurrence at 80 to 2292 days after surgery. One papillary-type tumor had cuboidal cells with scant cytoplasm and monomorphic nuclei, and the other had pseudostratified columnar cells with abundant cytoplasm. Immunohistochemistry revealed that the tumor cells in most cases were positive for cytokeratin (CK)7, CK20, KIT, and CD10, with the exception of cases of the solid type with clear cytoplasm (solid anaplastic), papillary type with columnar cells, and sarcomatoid types. A small number of tumor cells in the solid anaplastic and in the sarcomatoid types were positive for aquaporin-1. Increased expression of N-cadherin and Twist along with nuclear accumulation of β-catenin were observed in the sarcomatoid type. These results indicated that CK, KIT, and CD10 are relatively strongly expressed in most feline RCC. The solid anaplastic RCC exhibited CD10 expression with the absence of distal tubule marker expression. Although immunohistochemistry profiles were relatively consistent with those described in human RCC, the histopathologic features were different from those seen in humans. Epithelial-mesenchymal transition (EMT) marker expression in the current cases may suggest the involvement of an EMT-like mechanism in the development of sarcomatoid RCC in cats.
膀胱移行上皮癌の犬78例における治療成績の回顧的検討
愛宕 哲也; 佐伯 亘平; 木之下 怜平; 藤原 玲奈; 坪井 誠也; 中川 貴之; 西村 亮平
日本獣医麻酔外科学雑誌, 49, Suppl.1, 285, 285, (一社)日本獣医麻酔外科学会, 2018年06月
日本語
Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma.Akiko Inoue; Shingo Maeda; Ryohei Kinoshita; Masaya Tsuboi; Tomohiro Yonezawa; Naoaki Matsuki
Veterinary immunology and immunopathology, 190, 53, 56, Elsevier BV, 2017年08月,
［査読有り］,
［国際誌］英語, 研究論文（学術雑誌）, Although tumor-infiltrating lymphocytes (TILs) play a key role in anti-tumor immunity, their involvement in canine transitional cell carcinoma (TCC) is not well-documented. The objective of this study was to investigate the association between TIL number and prognosis in dogs with urinary bladder TCC. Immunohistochemical analysis of CD3 and granzyme B was performed using canine TCC (n=32) and normal bladder (n=10) tissues. The numbers of CD3+ and granzyme B+ cells located in peritumoral stroma of canine TCC were significantly higher than those in normal controls. In TCC cases, the number of CD3+ TILs was not significantly related to prognosis, whereas the abundant granzyme B+ TILs were associated with favorable outcome. Since granzyme B+ TILs were not associated with the tumor stage, the presence of granzyme B+ TILs may be an independent prognostic factor. These results suggest that granzyme B+ TILs play a role in anti-tumor immunity and inhibit tumor progression in canine TCC.
【QOLを改善するためのレスキュー療法】下部消化管閉塞への対応
木之下 怜平; 中川 貴之
Veterinary Oncology, 3, 2, 50, 54, (株)エデュワードプレス, 2016年04月
日本語
犬における原発性腎腫瘍の回顧的検討
木之下 怜平; 佐伯 亘平; 坪井 誠也; 藤原 玲奈; 西村 亮平
獣医麻酔外科学雑誌, 45, Suppl.2, 188, 188, (一社)日本獣医麻酔外科学会, 2014年12月, ［査読有り］
日本語
犬における下部尿路移行上皮癌の回顧的検討(2005〜2011)
木之下 怜平; 佐伯 亘平; 坪井 誠也; 中川 貴之; 西村 亮平
獣医麻酔外科学雑誌, 44, Suppl.2, 244, 244, (一社)日本獣医麻酔外科学会, 2013年12月, ［査読有り］
日本語
肛門嚢アポクリン腺癌の犬の回顧的検討
木之下 怜平; 藤田 淳; 藤原 玲奈; 入江 なつは; 中川 貴之; 西村 亮平
獣医麻酔外科学雑誌, 44, Suppl.1, 208, 208, (一社)日本獣医麻酔外科学会, 2013年06月
日本語
犬尿路上皮癌におけるPDXモデルの樹立
森下 大暉; 木之下 怜平; 青島 圭佑; 細谷 謙次; 山崎 淳平; 滝口 満喜, 日本獣医学会学術集会講演要旨集, 165回, [B2P, 03], 2022年09月
(公社)日本獣医学会, 日本語
臨床的に間質性肺疾患と診断された犬25頭の回顧的検討
川上 侑記; 中村 健介; 新坊 弦也; 山根 由久; 大菅 辰幸; 竹内 恭介; 木之下 怜平; 細谷 謙次; 永田 矩之; 滝口 満喜, 北海道獣医師会雑誌, 66, 8, 286, 286, 2022年08月
(公社)北海道獣医師会, 日本語
胸管の単離遮断により治療した特発性乳び胸の犬の2例
細谷謙次; 大脇稜; 竹内恭介; 木之下怜平; 金尚昊; 奥村正裕, 日本獣医麻酔外科学会学術集会抄録集(Web), 103, 111, 112, 2022年02月
イヌの肝細胞腫瘍におけるDNAメチル化の網羅的解析
淺利 友; 山崎 淳平; Oo Thander; 細谷 謙次; 金 尚昊; 木之下 怜平; 竹内 恭介; 賀川 由美子; 佐々木 東; 中村 健介; 滝口 満喜, 日本獣医学会学術集会講演要旨集, 164回, [HSO, 30], 2021年09月
(公社)日本獣医学会, 日本語
長期生存している特発性被嚢性腹膜硬化症の猫の1例
前田 晴香; 横山 望; 木之下 怜平; 大田 寛; 岡田 一喜; 賀川 由美子; 滝口 満喜, 北海道獣医師会雑誌, 65, 8, 263, 263, 2021年08月
(公社)北海道獣医師会, 日本語
唾液腺造影CTおよび術中唾液腺染色が手術支援に有用であった犬の2例
竹内 恭介; 細谷 謙次; 新坊 弦也; 金 尚昊; 木之下 怜平; 奥村 正裕, 日本獣医麻酔外科学雑誌, 50, Suppl.2, 287, 287, 2019年12月
(一社)日本獣医麻酔外科学会, 日本語
定位手術的照射法により患肢を温存した脛骨軟骨肉腫の犬の1例
松本 創; 細谷 謙次; 出口 辰也; 弘川 治喜; 木之下 怜平; 金 尚昊; 奥村 正裕, 日本獣医麻酔外科学雑誌, 50, Suppl.2, 271, 271, 2019年12月
(一社)日本獣医麻酔外科学会, 日本語
はじめての会陰ヘルニア「筋肉フラップを用いた整復法」
木之下怜平
獣医麻酔外科学会 北海道地区講習会, 2021年02月14日, 日本語, 公開講演，セミナー，チュートリアル，講習，講義等
2021年02月14日 - 2021年02月14日, ［招待講演］
獣医学での植皮術
木之下怜平
第97回日本獣医麻酔外科学会, 2019年01月12日, 日本語, 公開講演，セミナー，チュートリアル，講習，講義等
2019年01月12日 - 2019年01月13日, ［招待講演］
猫の閉塞性尿管結石に対する尿管切開および尿管膀胱新吻合術と閉鎖吸引ドレーンの併用の短期・中期的予後
木之下怜平
The 8th Annual AiSVS Congress, 2018年12月02日, 英語, ポスター発表
2018年12月01日 - 2018年12月02日
犬の尿管閉塞 私の解除法
木之下怜平
日本獣医麻酔外科学会東京地区講習会, 2018年03月04日, 日本語, 公開講演，セミナー，チュートリアル，講習，講義等
2018年03月04日 - 2018年03月04日, ［招待講演］
尿路のツマリの解除法
木之下怜平
日本獣医内科学アカデミー学術大会, 2017年02月18日, 日本語, 公開講演，セミナー，チュートリアル，講習，講義等
2017年02月17日 - 2017年02月19日, ［招待講演］
伴侶動物獣医療実習, 2024年, 学士課程, 獣医学部
アドバンスト演習, 2024年, 学士課程, 獣医学部
プレクリニカル実習, 2024年, 学士課程, 獣医学部
アドバンスト演習, 2024年, 学士課程, 獣医学部
伴侶動物獣医療実習Ⅰ, 2024年, 学士課程, 獣医学部
伴侶動物獣医療実習Ⅰ, 2024年, 学士課程, 獣医学部
伴侶動物獣医療実習Ⅱ, 2024年, 学士課程, 獣医学部
伴侶動物獣医療実習Ⅱ, 2024年, 学士課程, 獣医学部
プレクリニカル実習, 2024年, 学士課程, 獣医学部
